ACADIA to Host Conference Call and Webcast on Wednesday, March 1, 2006, at5:00 p.m. Eastern Time
SAN DIEGO, Feb. 22 /PRNewswire-FirstCall/ —ACADIA Pharmaceuticals Inc.(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments for centralnervous system disorders, today announced that it will report its unauditedfinancial results for the fourth quarter and year ended December 31, 2005 onWednesday, March 1, 2006, after the U.S. financial markets close.
Uli Hacksell, Ph.D., Chief Executive Officer, and Thomas H. Aasen, VicePresident and Chief Financial Officer, will host a conference call and webcaston Wednesday, March 1, 2006 at 5:00 p.m. Eastern Time to discuss ACADIA'sfinancial results and provide an update on the company's development programs.
The conference call may be accessed by dialing 866-713-8562 forparticipants in the U.S. or Canada and 617-597-5310 for international callers(reference passcode 17247135). A telephone replay of the conference call maybe accessed through March 15, 2006 by dialing 888-286-8010 for callers in theU.S. or Canada and 617-801-6888 for international callers (reference passcode28684341). The conference call also will be webcast live on ACADIA's website,www.acadia-pharm.com, under the investors section and will be archived thereuntil March 15, 2006.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments for centralnervous system disorders. ACADIA currently has four drug programs in clinicaldevelopment as well as a portfolio of preclinical and discovery assetsdirected at large unmet medical needs, including schizophrenia, Parkinson'sdisease, neuropathic pain, and glaucoma. All of the drug candidates inACADIA's product pipeline emanate from discoveries made using its proprietarydrug discovery platform. ACADIA's corporate headquarters is located in SanDiego, California and it maintains research and development operations in bothSan Diego and Malmo, Sweden.
Contacts:
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief Financial Officer
(858) 558-2871